A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Feb 2018 Last checked against ClinicalTrials.gov record.
- 20 Feb 2018 Planned initiation date changed from 15 Dec 2017 to 1 Mar 2018.
- 04 Aug 2016 New trial record